Meladinine

Methoxsalen, the active ingredient in Meladinine, is a psoralen presented as an oral formulation for oral use. It is employed to treat psoriasis and vitiligo in adult patients.

GNH USA supplies Meladinine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meladinine (methoxsalen) is used as a photosensitizing agent in dermatologic conditions that respond to UVA‑activated therapy.

- Psoriasis: reduces plaque formation and scaling when combined with controlled UVA exposure. - Vitiligo: promotes repigmentation of depigmented skin patches when used with phototherapy. - Cutaneous T‑cell lymphoma (off‑label): may aid in disease control as an adjunct to UVA treatment.

Methoxsalen may cause a range of adverse reactions, from mild to severe, depending on individual sensitivity and exposure to UVA light.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Skin erythema: redness at treated sites. - Itching: pruritus in exposed areas. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Severe phototoxic reactions: blistering or burns after UVA exposure. - Hepatic enzyme elevation: abnormal liver function tests. - Hematologic abnormalities: anemia or leukopenia. - Anaphylaxis: rare systemic allergic response. - Persistent hyperpigmentation: lasting darkening of skin.

Before initiating therapy with Meladinine, several safety considerations should be observed.

- UVA exposure: limit exposure to prescribed wavelengths and durations. - Liver function: monitor hepatic enzymes periodically. - Pregnancy: avoid use unless benefits outweigh potential risks. - Concomitant photosensitizers: assess risk of additive phototoxicity. - Renal impairment: adjust monitoring as needed. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Methoxsalen can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antifungal azoles (e.g., ketoconazole): increase methoxsalen plasma levels. - CYP450 inducers (e.g., rifampin): reduce therapeutic effect. - Other photosensitizing agents (e.g., tetracyclines): heighten risk of severe phototoxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce contraceptive effectiveness. - Warfarin: monitor INR for potential anticoagulant effect changes.